regulatory
confidence high
sentiment negative
materiality 0.80
Entrada receives FDA clinical hold on IND for ENTR-601-44 in Duchenne muscular dystrophy
Entrada Therapeutics, Inc.
- Clinical hold placed on IND for ENTR-601-44, a potential treatment for DMD with exon 44 skippable mutations.
- FDA to provide official clinical hold letter within 30 days; Entrada will work to address concerns.
- No approved therapies exist for patients with exon 44 skippable mutations.
- Entrada plans to share updates after further communications with the FDA.